Radiation therapy for malignant phyllodes tumor of the breast: An analysis of SEER data
- PMID: 28013032
- DOI: 10.1016/j.breast.2016.12.006
Radiation therapy for malignant phyllodes tumor of the breast: An analysis of SEER data
Abstract
Purpose: Malignant phyllodes tumor of the breast (MPTB) accounts for less than 1% of whole breast neoplasm. Surgery is regarded as the primary treatment of choice in patients with MPTB, but the necessity of postoperative radiation therapy (RT) has been a subject of debate. Our aim was to evaluate effects of postoperative RT for MPTB using a large population database.
Methods: Using the Surveillance, Epidemiology, and End Results Program (SEER) database (1983-2013), clinico-pathologic prognostic factors were evaluated. Postoperative RT, tumor extent, grade, and lymph node (LN) metastasis were included in the analysis. Univariate and multivariate Cox proportional hazards regressions were performed to evaluate prognostic power of variables on cancer specific survival (CSS).
Results: A total of 1974 patients with MPTB were reviewed. Of these, 825 (42%) and 1149 (58%) patients underwent mastectomy and breast conserving surgery (BCS), respectively. In each group, 130 (16%) and 122 (11%) patients received postoperative RT. For patients with adverse risk factors including high grade and large tumor size, postoperative RT was more likely to be performed. In multivariate analysis, age, ethnicity, tumor size, tumor extension and LN status were correlated with prognosis in mastectomy group, while postoperative RT did not affect CSS. In BCS group, age and grade were significant prognostic factors on CSS, meanwhile postoperative RT did not impact CSS in multivariate analysis.
Conclusion: Although patients with more adverse prognostic factors underwent postoperative RT, RT groups were not inferior to non-RT group on CSS regardless of surgery (mastectomy or BCS).
Keywords: Malignant phyllodes tumor; Radiotherapy; SEER data.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
-
Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program.Cancer. 2006 Nov 1;107(9):2127-33. doi: 10.1002/cncr.22228. Cancer. 2006. PMID: 16998937
-
The role of adjuvant radiotherapy in patients with malignant phyllodes tumor of the breast: a propensity-score matching analysis.Breast Cancer. 2021 Jan;28(1):110-118. doi: 10.1007/s12282-020-01135-7. Epub 2020 Aug 3. Breast Cancer. 2021. PMID: 32748225 Free PMC article.
-
Risk Factors for Recurrence of Malignant Phyllodes Tumors of the Breast.In Vivo. 2019 Jan-Feb;33(1):263-269. doi: 10.21873/invivo.11470. In Vivo. 2019. PMID: 30587634 Free PMC article.
-
Phyllodes tumors of the breast.Curr Treat Options Oncol. 2001 Apr;2(2):139-47. doi: 10.1007/s11864-001-0056-y. Curr Treat Options Oncol. 2001. PMID: 12057132 Review.
-
Cystosarcoma phyllodes: mastectomy, lumpectomy, or lumpectomy plus irradiation.Surg Oncol. 2000 Aug;9(2):49-52. doi: 10.1016/s0960-7404(00)00022-0. Surg Oncol. 2000. PMID: 11094322 Review. No abstract available.
Cited by
-
Phyllodes Tumors of the Breast: Canadian National Consensus Document Using Modified Delphi Methodology.Ann Surg Oncol. 2023 Oct;30(11):6386-6397. doi: 10.1245/s10434-023-13912-7. Epub 2023 Aug 9. Ann Surg Oncol. 2023. PMID: 37556009 Review.
-
Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing.Ann Surg Oncol. 2020 Oct;27(10):3633-3640. doi: 10.1245/s10434-020-08480-z. Epub 2020 Jun 5. Ann Surg Oncol. 2020. PMID: 32504368 Free PMC article.
-
Radiotherapy with apatinib for recurrence of malignant phyllodes tumor of the breast: A case report.Medicine (Baltimore). 2020 Jan;99(3):e18808. doi: 10.1097/MD.0000000000018808. Medicine (Baltimore). 2020. PMID: 32011486 Free PMC article.
-
The application of clinical variable-based nomogram in predicting overall survival in malignant phyllodes tumors of the breast.Front Genet. 2023 May 30;14:1133495. doi: 10.3389/fgene.2023.1133495. eCollection 2023. Front Genet. 2023. PMID: 37323673 Free PMC article.
-
MR-guided 125I seed implantation treatment for maxillofacial malignant tumor.J Appl Clin Med Phys. 2021 Jan;22(1):92-99. doi: 10.1002/acm2.13112. Epub 2020 Dec 9. J Appl Clin Med Phys. 2021. PMID: 33295143 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical